Diabetes Mellitus Type 2 — Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)
Citation(s)
A Multicenter, Randomized, Double-Blind, Placebo Controlled 36 Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant in Patients With Type 2 Diabetes